Clinical trials: Surfactant
Acute Respiratory Distress Syndrome
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study was to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in hospitalized adult patients diagnosed with SARS-COV-19 acute respiratory distress…
- Trial name
- NCT04502433
- Testing
- CUROSURF® (poractant alfa)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 22 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Respiratory Distress Syndrome, Preterm Birth
LISA vs INSURE in Extremely Low Birth Weight Infants. A Manikin Study
This is an unblinded, randomized, controlled, crossover (AB/BA) trial of surfactant treatment with LISA vs. INSURE in a manikin simulating an extremely low birth weight infant.
- Conditions
- Respiratory Distress Syndrome, Preterm Birth, Surfactant Deficiency Syndrome Neonatal
- Trial name
- NCT04944108
- Testing
- LISA approach, Insure approach
- Where
- 2 sites in Italy
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University Hospital Padova
Respiratory Distress Syndrome in Premature Infant
Respiratory Effect of the LISA Method With Sedation by Propofol Versus Absence of Sedation.
The investigators propose to evaluate premedication with Propofol compared to a control strategy including a placebo with a possible rescue treatment with ketamine to ensure pain control before LISA Procedure .
- Trial name
- PROLISA (NCT04016246)
- Testing
- Propofol-Lipuro
- Where
- 13 sites in France
- Volunteers
- 233 people
- Sponsor
- University Hospital, Grenoble
Respiratory Distress Syndrome
Minimally Invasive Surfactant Therapy Followed by CPAP (MISTCPAP) in Preterm Infants With RDS
There is a reducing incidence of pneumothorax, PIE and the combined outcome of death or BPD since the development of Surfactant therapy.
- Trial name
- MISTCPAP (NCT01723683)
- Testing
- Surfactant
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Respiratory Distress Syndrome
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
The primary objective of this research is to compare the need for intubation and mechanical ventilation in the first seven days of life for infants with respiratory distress syndrome (RDS) on nasal continuous positive airway…
- Trial name
- NCT01116921
- Testing
- Nasal continuous positive airway pressure (nCPAP), Laryngeal Mask Airway (LMA) to deliver surfactant, Surfactants, Pulmonary
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- University of Minnesota
Respiratory Distress Syndrome
Early CPAP And Large Volume Minimally Invasive Surfactant (ECALMIST) in Preterm Infants With RDS
Modification of Minimally Invasive Surfactant Therapy (MIST) to a new technique called ECALMIST (Early CPAP And Large volume Minimal Invasive Surfactant).
- Trial name
- ECALMIST (NCT01553292)
- Testing
- ECALMIST
- Where
- 3 sites in Canada
- Volunteers
- 21 people
- Sponsor
- University of Manitoba
Respiratory Distress Syndrome, Newborn
Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome
In this study, newborn babies with respiratory distress syndrome (RDS), receiving oxygen via nasal continuous airway pressure (CPAP) modalities, and needing surfactant treatment will be randomized to standard delivery of…
- Trial name
- NCT02164734
- Testing
- Endotracheal intubation, Laryngeal mask airway, remifentanil
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Albany Medical College
Respiratory Distress Syndrome, Preterm Pregnancy
Less Invasive Surfactant Administration in Late Preterm or Early Term Born Infants
The aim of this study is to see if giving less invasive surfactant administration (LISA) during high-flow nasal cannula (HFNC) oxygen treatment reduces the need for invasive ventilation in babies with breathing problems born 2-6…
- Conditions
- Respiratory Distress Syndrome, Preterm Pregnancy, Surfactant Deficiency Syndrome Neonatal
- Trial name
- NCT06421506
- Testing
- Less invasive surfactant administration during high flow nasal cannula treatment
- Where
- United Kingdom
- Volunteers
- 245 people
- Sponsor
- King's College Hospital NHS Trust
Regional Blood Flow, Premature Birth
Common Neonatal Procedures Could Affect the aEEG in <30 Weeks of Gestational Age Preterms
Very low birth weight infants has increased dramatically their survival. Survival without neurologic disturbance varies a lot between centers.There is evidence that fluctuations in cerebral blood flow influences the appearance of…
- Conditions
- Regional Blood Flow, Premature Birth, Electroencephalography
- Trial name
- ELECTROPREM (NCT00722033)
- Testing
- 3 protocols of Indomethacin administration
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Respiratory Distress Syndrome, Newborn, Premature Birth
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required…
- Conditions
- Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
- Trial name
- NCT00215540
- Testing
- Lucinactant 175 mg/kg, Lucinactant 90 mg/kg
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Windtree Therapeutics
Acute Respiratory Distress Syndrome
KL₄Surfactant Treatment in Patients With ARDS
Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).
- Trial name
- NCT00215553
- Testing
- A.1 Lucinactant, B.3 SoC, A.2 Lucinactant
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Windtree Therapeutics
Respiratory Distress Syndrome in Premature Infant
Surfactant Therapy Via Supraglottic Airway to Preterm Neonates With RDS in Vietnam
Preterm babies often have trouble breathing because their lungs are not fully developed. This condition is called respiratory distress syndrome (RDS). A medicine called surfactant helps their lungs open up and work better.
- Trial name
- NEOSURF (NCT07098910)
- Testing
- Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA), Intubation - Surfactant administration - Extubation (INSURE)
- Where
- Vietnam
- Volunteers
- 440 people
- Sponsor
- Karolinska Institutet
Survival of Bacteria on Skin After Using Different Soaps
Analysis of the Effect of Antimicrobial Soap on Bacterial Survival
This study will recruit up to 10 healthy volunteers. An avirulent strain of S. pyogenes will be applied to their forearms after washing each of their forearms with different types of soap, one with an antimicrobial compound, and…
- Trial name
- NCT02012348
- Testing
- Antibacterial soap with triclocarban, Antibacterial soap + benzalkonium chloride, Control soap
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Respiratory Distress Syndrome, Neonatal Death
Implementing LISA Surfactant in Nigeria
Implement surfactant (BLES®) replacement therapy using the Less Invasive Surfactant Administration technique in six tertiary institutions in Nigeria and evaluate its impact on 72-hour neonatal mortality in premature infants born…
- Trial name
- NCT05714865
- Testing
- Surfactant
- Where
- 6 sites in Nigeria
- Volunteers
- 349 people
- Sponsor
- Indiana University
Neonates and Preterm Infants, Infant Respiratory Distress Syndrome
Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minutes Versus 5 Minutes
Respiratory distress syndrome (RDS) is common in very preterm infants due to surfactant deficiency. Surfactant replacement therapy is lifesaving, and current guidelines recommend the less invasive surfactant administration (LISA)…
- Conditions
- Neonates and Preterm Infants, Infant Respiratory Distress Syndrome, Surfactant Deficiency Syndrome Neonatal, Surfactant
- Trial name
- SurfStab I (NCT07261787)
- Testing
- Poractant alfa (Curosurf®) - 1-minute administration, Poractant alfa (Curosurf®) - 5-minute administration
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Medical University of Graz
Neonatal Respiratory Distress
Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)
Surfactant replacement therapy can be life-saving for newborn infants born with symptomatic lung surfactant deficiency causing Respiratory Distress Syndrome (RDS).
- Trial name
- NCT03582930
- Testing
- Infasurf Aero
- Where
- 5 sites in United States
- Sponsor
- ONY
Respiratory Distress Syndrome, Surfactant Administration by Aerosolization
Does The Surfactant Administration by Aerosolization Effective?
The present study was designed to evaluate, in premature babies with RDS breathing spontaneously, the efficacy of combined treatment with nasal continuous positive airway pressure (CPAP) and aerosolized surfactant.
- Trial name
- NCT02825953
- Testing
- surfactant, nasal continuous positive airway pressure, non-invasive intermittent positive-pressure ventilation
- Volunteers
- 75 people
- Sponsor
- nihat demir
Dermatitis, Atopic, Rosacea
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
The purpose of this study is to evaluate the efficacy and tolerance of a gentle facial cleanser in participants with sensitive skin (eczema/atopic dermatitis, rosacea, acne, cosmetic intolerance syndrome).
- Conditions
- Dermatitis, Atopic, Rosacea, Acne Vulgaris, Sensitive Skin
- Trial name
- NCT05094700
- Testing
- Non-marketed Cosmetic Facial Cleanser
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Respiratory Distress Syndrome, Newborn
Aerosolized Surfactant in Neonatal RDS
Respiratory distress syndrome (RDS), caused by surfactant deficiency, is the leading cause of mortality and morbidity in preterm infants.
- Trial name
- AS-02 (NCT02294630)
- Testing
- Surfactant
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Sood, Beena G., MD, MS
Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction), Bronchopulmonary Dysplasia
Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide
The purpose of this study is to determine if the combination of late doses of Infasurf with inhaled nitric oxide will interact to improve the surfactant function and thus the respiratory status and outcome of treated infants.
- Trial name
- TOLSURFPilot (NCT00569530)
- Testing
- Infasurf (ONY Inc.)
- Where
- 9 sites in United States
- Volunteers
- 85 people
- Sponsor
- Roberta Ballard